Accéder au contenu
Merck
Toutes les photos(2)

Key Documents

C2331

Sigma-Aldrich

Monoclonal Anti-Carcinoembryonic Antigen antibody produced in mouse

clone C6G9, ascites fluid

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Numéro MDL:
Code UNSPSC :
12352203
Nomenclature NACRES :
NA.46

Source biologique

mouse

Niveau de qualité

Conjugué

unconjugated

Forme d'anticorps

ascites fluid

Type de produit anticorps

primary antibodies

Clone

C6G9, monoclonal

Contient

15 mM sodium azide

Espèces réactives

human

Technique(s)

flow cytometry: suitable
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:8,000 using human colon carcinoma tissue
western blot: suitable

Isotype

IgG1

Numéro d'accès UniProt

Conditions d'expédition

dry ice

Température de stockage

−20°C

Modification post-traductionnelle de la cible

unmodified

Informations sur le gène

human ... CEACAM5(1048)

Description générale

Carcinoembryonic Antigen (CEA) is a member of the immunoglobulin superfamily that regulates cellular signaling and adhesion. CEA inhibits cell differentiation and subsequently facilitates tumor growth . Thus, CEA has been implicated in various cancers, including colorectal, lung and breast tumors
Monoclonal Anti-Human Carcinoembryonic Antigen (CEA) reacts specifically with human CEA (CD66e, 180 kDa) from different types of malignant tissues. The antibody detects an epitope which is resistant to 30 minute oxidation by 1% sodium periodate solution in formalin-fixed, paraffin-embedded tissue sections. Enzymatic predigestion with proteolytic enzymes enhances immunohistochemical staining with the antibody.The product reacts with medullary thyroid cancers and also associates with cell surface and cytoplasm of malignant glands in colorectal adenocarcinomas. Additionally, the product reacts weakly with normal colon mucosa and occasionally reacts with bile canalicular and pancreatic acinar cells. However, the antibody does not react with other tested tissue such as term placenta, nor does it bind to non-specific cross-reacting antigen (NCA) in granulocytes.
Carcinoembryonic Antigen (CEA) is located on human chromosome 19q13.2.

Spécificité

The antibody reacts specifically with human CEA (CD66e, 180 kDa) from several types of malignant tissue including colorectal, lung and breast tumors. It also stains medullary carcinomas of the thyroid. The product reacts strongly with the cell surface and cytoplasm of malignant glands in colorectal adenocarcinomas. A weak reactivity is seen with normal colon mucosa and occasionally with bile canalicular and pancreatic acinar cells, but not with other tested tissue including term placenta. There is no cross-reactivity with non-specific cross-reacting antigen (NCA) present in granulocytes, using immunoblotting, flow cytometry and immunohistochemical techniques. The antibody recognizes an epitope that is resistant to 30 minute oxidation by 1% sodium periodate solution in routine formalin-fixed and paraffin-embedded tissue sections. Enzymatic predigestion with proteolytic enzymes improves immunohistochemical staining with the antibody.

Immunogène

carcinoembryonic antigen (CEA) isolated from a human colon adenocarcinoma cell line.

Application

Monoclonal Anti-Carcinoembryonic Antigen antibody is suitable for use in immunohistochemistry (1:8,000 using formalin-fixed, paraffin-embedded sections of human colon carcinoma tissue).
Monoclonal Anti-Carcinoembryonic Antigen antibody produced in mouse has been used in western blot analysis and surface plasmon resonance (SPR) based immunoassay.

Actions biochimiques/physiologiques

Carcinoembryonic Antigen (CEA) inhibits tumor growth in colon, hepatoma and prostate cancers.

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Vous ne trouvez pas le bon produit ?  

Essayez notre Outil de sélection de produits.

Code de la classe de stockage

10 - Combustible liquids

Classe de danger pour l'eau (WGK)

nwg

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Maria Jeppesen et al.
PloS one, 12(9), e0183074-e0183074 (2017-09-07)
Chemotherapy treatment of cancer remains a challenge due to the molecular and functional heterogeneity displayed by tumours originating from the same cell type. The pronounced heterogeneity makes it difficult for oncologists to devise an effective therapeutic strategy for the patient.
The role of the carcinoembryonic antigen receptor in colorectal cancer progression
Bajenova O, et al.
Journal of integrative oncology., 6(2), 192-192 (2017)
Virna Cortez-Retamozo et al.
Cancer research, 64(8), 2853-2857 (2004-04-17)
Nanobodies are the smallest fragments of naturally occurring single-domain antibodies that have evolved to be fully functional in the absence of a light chain. Nanobodies are strictly monomeric, very stable, and highly soluble entities. We identified a nanobody with subnanomolar
Characterizing the Tumor Suppressor Role of CEACAM1 in Multiple Myeloma
Xu J, et al.
Cellular Physiology and Biochemistry, 45(4), 1631-1640 (2018)
Stefan Gratz et al.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 60(4), 413-423 (2014-10-18)
The aim of this retrospective study was to compare the targeting of "pure" osteomyelitis (i.e., without surrounding soft tissue infection) by directly 99mTc-labelled complete immunoglobulin G (IgG) monoclonal antibody (MAb) ([99mTc]besilesomab) and by directly 99mTc-labelled fragment antigen-binding (FAb) MAb ([99mTc]sulesomab)

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique